Anaptysbio Stock Investor Sentiment

ANAB Stock  USD 24.10  1.83  8.22%   
About 59% of AnaptysBio's investor base is looking to short. The analysis of the overall investor sentiment regarding AnaptysBio suggests that many traders are alarmed. The current market sentiment, together with AnaptysBio's historical and current headlines, can help investors time the market. In addition, many technical investors use AnaptysBio stock news signals to limit their universe of possible portfolio assets.
  

AnaptysBio Sentiment by Major News Outlets

Investor sentiment, mood or attitude towards AnaptysBio can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
over six months ago at seekingalpha.com         
AnaptysBio GAAP EPS of -1.64 misses by 0.04
seekingalpha News
over six months ago at investing.com         
AnaptysBio reports positive phase 3 GPP trial results
Investing News at Macroaxis
over six months ago at globenewswire.com         
Anaptys Announces Positive Top-Line GEMINI-2 Phase 3 Clinical Trial Results of Imsidolimab in Genera...
Macroaxis News: globenewswire.com
over six months ago at finance.yahoo.com         
Anaptys Announces First Quarter 2024 Financial Results and Provides Business Update
Yahoo News
over six months ago at finance.yahoo.com         
Anaptys Announces Positive Top-Line GEMINI-2 Phase 3 Clinical Trial Results of Imsidolimab in Genera...
Yahoo News
over six months ago at benzinga.com         
Anaptys to Receive 50 Million in a Capped Non-Recourse Monetization from Amended Agreement with Saga...
benzinga news
over six months ago at finance.yahoo.com         
Anaptys to Receive 50 Million in a Capped Non-Recourse Monetization from Amended Agreement with Saga...
Yahoo News
over six months ago at zacks.com         
Iovance Gears Up for Q1 Earnings Heres What to Expect
zacks News
over six months ago at www.macroaxis.com         
Acquisition by Schmid John P. of 16510 shares of AnaptysBio at 21.19 subject to Rule 16b-3
Macroaxis News
over six months ago at www.macroaxis.com         
Disposition of 5000 shares by Eric Loumeau of AnaptysBio at 14.02 subject to Rule 16b-3
Macroaxis News
over six months ago at finance.yahoo.com         
Hidradenitis Suppurativa Pipeline Analysis Report 2024 Featuring 24 Companies and 24 Pipeline Drugs ...
Yahoo News
over six months ago at simplywall.st         
AnaptysBio adds US184m to market cap in the past 7 days, though investors from five years ago are st...
Simply Wall St News at Macroaxis
over six months ago at zacks.com         
AnaptysBio Soars 14.3 percent Is Further Upside Left in the Stock?
zacks News
over six months ago at finance.yahoo.com         
Disposition of 5000 shares by Eric Loumeau of AnaptysBio at 25.0 subject to Rule 16b-3
Yahoo News
over six months ago at finance.yahoo.com         
AnaptysBio Soars 14.3 percent Is Further Upside Left in the Stock?
Yahoo News
Far too much social signal, news, headlines, and media speculation about AnaptysBio that are available to investors today. That information is available publicly through AnaptysBio media outlets and privately through word of mouth or via AnaptysBio internal channels. However, regardless of the origin, that massive amount of AnaptysBio data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of AnaptysBio news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of AnaptysBio relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to AnaptysBio's headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive AnaptysBio alpha.

AnaptysBio Performance against Dow Jones

 Price Growth (%)  
       Timeline  
1
Disposition of 1300 shares by Orwin John A of AnaptysBio subject to Rule 16b-3
09/13/2024
2
Disposition of 10000 shares by Dennis Mulroy of AnaptysBio at 40.13 subject to Rule 16b-3
09/16/2024
3
Disposition of 3780 shares by Eric Loumeau of AnaptysBio at 38.4103 subject to Rule 16b-3
09/17/2024
4
TANG CAPITAL MANAGEMENT LLC Acquires New Stake in Singular Genomics Systems Inc
09/18/2024
5
Disposition of 5000 shares by Eric Loumeau of AnaptysBio at 14.02 subject to Rule 16b-3
10/14/2024
6
AMD, Eli Lilly slide Google, Visa rise among Wednesdays afternoon market cap stock movers
10/30/2024
7
HC Wainwright Reaffirms Buy Rating for AnaptysBio
10/31/2024
8
AnaptysBio GAAP EPS of -1.14 beats by 0.51, revenue of 30.02M beats by 21.85M
11/05/2024
9
Revenue Rises to 30M in AnaptysBio Inc. Q3 2024, EPS of -1.14 Exceeds Estimates
11/06/2024
10
AnaptysBio, Inc. May Have Run Too Fast Too Soon With Recent 33 percent Price Plummet
11/07/2024
11
AnaptysBio Upgraded to Buy What Does It Mean for the Stock
11/08/2024
12
Disposition of 2000 shares by Lizzul Paul F. of AnaptysBio at 40.0 subject to Rule 16b-3
11/22/2024

Complementary Tools for AnaptysBio Stock analysis

When running AnaptysBio's price analysis, check to measure AnaptysBio's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy AnaptysBio is operating at the current time. Most of AnaptysBio's value examination focuses on studying past and present price action to predict the probability of AnaptysBio's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move AnaptysBio's price. Additionally, you may evaluate how the addition of AnaptysBio to your portfolios can decrease your overall portfolio volatility.
ETFs
Find actively traded Exchange Traded Funds (ETF) from around the world
Options Analysis
Analyze and evaluate options and option chains as a potential hedge for your portfolios
Volatility Analysis
Get historical volatility and risk analysis based on latest market data
Portfolio Dashboard
Portfolio dashboard that provides centralized access to all your investments